Sponsor: Boehringer Ingelheim Pharmaceuticals
Sponsor Study ID: 1403-0008
Study Title: Brightline 1: A Phase II/III, randomized, open label, multi center study of BI 907828 compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma
CTO #: 103494
NCT Number: NCT05218499
Phase: II/III
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Soft Tissue
Study Objectives: